FDA Announces Sweeping Plan To Review Safety Of Surgical Staplers
The FDA said it might reclassify the widely used devices featured in a recent Kaiser Health News investigation.
The independent source for health policy research, polling, and news.
1,941 - 1,960 of 3,883 Results
The FDA said it might reclassify the widely used devices featured in a recent Kaiser Health News investigation.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Most hospitals appear to be complying with the federal rule to post their prices online. Yet there is little follow-up by the government or industry and debate continues about whether the price lists are creating more confusion than clarity among consumers.
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss the resignation of Food and Drug Administration Commissioner Scott Gottlieb, the latest on federal and state efforts to shore up the Affordable Care Act; and how public health officials plan to persuade parents who are reluctant to vaccinate their kids. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
The Food and Drug Administration has let medical device companies file reports of injuries and malfunctions outside a widely scrutinized public database, leaving doctors and medical sleuths in the dark.
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent “unapproved” and “misbranded” drugs to U.S. consumers, jeopardizing their safety.
A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.
A proposed state law with bipartisan, bicameral support is on the move in Texas. It would force hospitals and insurers to settle surprise bills — instead of relying on patients to start the mediation process. The KHN/NPR "Bill of the Month" series is a catalyst for the effort.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
KHN correspondent Emmarie Huetteman appeared on the C-SPAN program “Washington Journal,” where she fielded viewers’ calls about high drug prices and industry criticism.
The penalties are part of a program set up by the Affordable Care Act to prompt hospitals to pay more attention to safety issues that can lead to injuries, such as falls or hospital-acquired infections.
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHN’s Julie Rovner to discuss the new “Medicare-for-all” bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHN’s Julie Appleby about the latest “Bill of the Month” installment.
An animal lover stopped to feed a hungry-looking stray cat outside Everglades National Park in Florida. First, the cat bit her finger — then the hospital billed her close to $50,000 for a treatment that typically costs about $3,000.
Carol Marley has pancreatic cancer — and dealing with its financial toll has become her full-time job.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Most hearings before the U.S. House and Senate are routine affairs. But a few tense moments featuring everyone from Hillary Clinton to tobacco CEOs drew the attention of millions of Americans.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Confrontational hearings 60 years ago sparked remarkably similar quotes about drug prices and health care policy.
© 2026 KFF